mitoxantrone has been researched along with Myeloproliferative Disorders in 5 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of around 50% in patients with advanced breast cancer." | 9.07 | Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer. ( Ashley, S; Montes, A; Nicolson, M; O'Brien, ME; Powles, TJ; Tidy, A, 1994) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 7.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| "The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of around 50% in patients with advanced breast cancer." | 5.07 | Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer. ( Ashley, S; Montes, A; Nicolson, M; O'Brien, ME; Powles, TJ; Tidy, A, 1994) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 3.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| "Awareness that trisomy 21 bearing leukaemia in the neonatal period can be transient even in the absence of Down's syndrome is important to prevent unnecessary treatment." | 1.30 | Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome. ( Readett, D; Richards, M; Vora, AJ; Watmore, A; Welch, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palmieri, R | 1 |
| Othus, M | 1 |
| Halpern, AB | 1 |
| Percival, MM | 1 |
| Godwin, CD | 1 |
| Becker, PS | 1 |
| Walter, RB | 1 |
| Girsberger, S | 1 |
| Karow, A | 1 |
| Lundberg, P | 1 |
| Dirnhofer, S | 1 |
| Lehmann, T | 1 |
| Passweg, JR | 1 |
| Tichelli, A | 1 |
| Skoda, R | 1 |
| Rovó, A | 1 |
| Coleman, RE | 1 |
| Maisey, MN | 1 |
| Knight, RK | 1 |
| Rubens, RD | 1 |
| O'Brien, ME | 1 |
| Nicolson, M | 1 |
| Montes, A | 1 |
| Tidy, A | 1 |
| Ashley, S | 1 |
| Powles, TJ | 1 |
| Richards, M | 1 |
| Welch, J | 1 |
| Watmore, A | 1 |
| Readett, D | 1 |
| Vora, AJ | 1 |
1 trial available for mitoxantrone and Myeloproliferative Disorders
| Article | Year |
|---|---|
Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Dose-Respo | 1994 |
4 other studies available for mitoxantrone and Myeloproliferative Disorders
| Article | Year |
|---|---|
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribi | 2020 |
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Topics: Alleles; Antineoplastic Agents; Bone Marrow Neoplasms; Drug Therapy, Combination; Etoposide; Humans; | 2013 |
Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1984 |
Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Cytarabine; Down Syndrom | 1998 |